As personalized, low-volume, high-value therapies like CAR-T and cell & gene treatments scale, both manufacturers and specialty couriers are facing unprecedented cost and capacity pressures. While these therapies are medically transformative, their logistics requirements, ultra-cold conditions, patient-specific handling, and ad hoc routing, can make transportation prohibitively expensive and operationally inefficient. This panel brings together pharma leaders and key specialty providers to unpack how both sides can rethink partnership models, cost structures, service design, and shared incentives to ensure these therapies remain viable, accessible, and sustainable.

• Align pricing models and service expectations by building transparent, long-term partnerships that reflect true volume, risk, and operational complexity
• Optimize cost drivers by exploring shared capacity, hub strategies, and alternative service designs that reduce reliance on one-off, high-cost lanes
• Collaborate earlier in therapy and network design to ensure courier capabilities, manufacturing realities, and patient needs are integrated into a scalable, affordable logistics model